Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027KT-621 BREADTH Phase 2b trial in asthma on track to ...

Patients receiving oral niacinamide for nonmelanoma skin cancer chemoprophylaxis show fewer cardiac events, a retrospective ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that adults with seborrheic ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

A retrospective study found a higher prevalence of several autoimmune and inflammatory conditions, in addition to skin ...

My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three ...